Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 17

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  szczepionki rekombinowane
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
The aim of the paper was the presentation of the newest information regarding abilities to prevent swine influenza using conventional vaccines and technologically advanced preparations obtained by using genetic engineering. In the 90s most swine influenza isolates were closely related to human influenza virus and therefore the vaccine based on human virus type A, subtype H3N2, was widely used. Due to its subsequently decreased efficacy, resulting from antigenic drift and shift as well as the occurrence of new reasorrtants, a new generation of preparations was elaborated. Induction of natural protection against influenza virus is correlated with non-mutation-dependant antibodies, therefore the use of genes coding conserve proteins for immunoprophylaxis was tested. The use of protein NS1 as a differentiation marker between naturally exposed and vaccinated animals, as well as protein NP as an antigen inducing effective cell-mediated and humoral immunological response were suggested. Much attention was given to the selection of gene carriers like plasmid vectors and recombinant viruses; the mechanism of cross-immunoprotection between SIV subtypes; and the adjuvant function. Currently we have no commercially available new generation vaccine that would be able to guarantee spectacular results of immunization for pig breeders, but we have to underline that pilot studies on animals models have as a goal the development of effective tools for the protection of humans against influenza.
Infectious laryngotracheitis (ILT) is a highly contagious, acute disease of the respiratory system in chickens worldwide. Clinically the disease may occur in a wide range of severity - from subacute to peracute form. Latency of the ILT virus is commonly observed in the course of this disease. In this study special attention was paid to describing the latency of the ILT virus, its mechanisms, and dangerous consequences. Live attenuated vaccines are commonly used in the immunoprophylaxis against the ILT which, despite their effectiveness, have a number of shortcomings. One of them is the possibility of virulence reversion of the vaccine virus strains, which can directly cause the outbreak of the disease. Considering the above, it seems necessary to improve the current immunoprophylaxis strategies with the use of new, safer and equally efficient vaccines. This article presents the basic advantages and disadvantages of the future vaccines against the ILT i.a. vector vaccines as well as the DNA vaccines. High hopes are associated with the results of the research on the development of a gene deletion vaccine. This vaccine seems to achieve the requirements for the ideal vaccines (high immunogenicity, manageability, lack of reversion of the virulence).
The article reviews the history, present status and the future of Bluetongue BT vaccines and prophylactic vaccinations against BT in Europe. To date, attenuated (modified live viruses, MLV) and inactivated virus preparations vaccines against BTV serotypes 2 and 4 were developed and used in the field. Moreover, virus-like particles (VLPs) produced from recombinant baculovirus and live recombinant vaccinia or canarypox virus-vectored vaccines were tested in the laboratory. The main aims of BT vaccination strategy are as follows: to prevent clinical disease, the reduction of the spread of the BT virus in the environment and to safeguard the movement of susceptible animals between affected and free zones. The mass vaccinations of all susceptible animals are the most efficient veterinary method to fight against BT and a harmonized strategy for vaccinations in Europe would improve the intra-Community trade of live animals. The amount of BT vaccines needed for the protection of the European livestock exceed 220 million doses, including about 150 million doses of BTV serotype 8. In January 2008, the Intervet International B.V., as the first vaccine producer, has developed a vaccine against BTV serotype 8 for sheep and cattle and declared the delivery of the first quantities of vaccine on the European trade in May 2008. The BT eradication policy combining administrative methods and prophylactic vaccination of all susceptible animals, completed with application of insecticides - pesticides to control Culicoides midges in the environment - is currently the most effective method of fighting against BT.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.